Ревматоидный артрит и беременность
https://doi.org/10.14412/1995-4484-2014-589-599
Аннотация
Ревматоидный артрит (РА) обычно начинается в том возрасте, когда вопрос материнства для многих женщин уже решен, однако он может дебютировать в детском и подростковом возрасте. Кроме того, в последние годы прослеживается тенденция планирования беременности женщинами в более зрелом возрасте, что диктует необходимость обсуждения проблемы гестации при данном заболевании. Изучение механизмов влияния беременности на развитие РА как в период гестации, так и в отдаленные сроки имеет важное теоретическое и практическое значение. Результаты таких исследований могут быть использованы при разработке новых методов лечения РА и тактики ведения больных в период беременности и лактации. В статье приведены данные литературы о фертильности при РА, влиянии беременности на активность РА и последнего на течение и исходы гестации, представлены современные воззрения на лактацию и применение оральных контрацептивов при РА. Особое внимание уделено лекарственной терапии беременных и кормящих женщин с РА: подробно рассмотрены группы антиревматических препаратов в соответствии с безопасностью или потенциальным риском их применения. Предложены терапевтический алгоритм и рекомендации по планированию беременности и наблюдению за пациентками с РА в период гестации.
Об авторах
Н. М. Кошелева
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34А
Россия
Россия
Е. В. Матьянова
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34А
Россия
Россия
Список литературы
1. Сosta M, Colia D. Treating infertility in autoimmune patients. Rheumatology (Oxford). 2008;47 Suppl 3:iii38–41.
2. Huong DL, Amoura Z, Duhaut P, et al. Risk of failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol. 2002;29:2571–6.
3. Stone S, Khamashta MA, Nelson-Piercy C. Nonsteroidal antiinflammatory drugs and reversible female infertility: is there a link? Drug Saf. 2002;25:545–51. DOI: http://dx.doi.org/10.2165/00002018-200225080-00001.
4. Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med. 2000;160:610–9. DOI: http://dx.doi.org/10.1001/archinte.160.5.610.
5. Skomsvoll JF, Wallenius M, Koksvik HS, et al. Drug insight: anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation. Nat Clin Pract Rheumatol. 2007;3(3):156–64. DOI: 10.1038/ncprheum0426.
6. Haga HJ, Gjesdal CG, Irgens LM, Ostensen M. Reproduction and gynaecological manifestations in omen with primary Sjogren's syndrome: a case-control study. Scand J Rheumatol. 2005;34(1):45–8. DOI: http://dx.doi.org/10.1080/03009740510017959.
7. Takaya M, Ichikawa Y, Shimizu H, et al. Sjogren's syndrome and pregnancy. Tokai J Exp Clin Med. 1991 Jul;16(2):83–8.
8. Andre M, Delevaux I, Amoura Z, et al. Ovarian vein thrombosis in the antiphospholipid syndrome. Arthritis Rheum. 2004 Jan:50(1):183–6. DOI: http://dx.doi.org/10.1002/art.11435.
9. Guballa N, Sammaritano L, Schwartzman S, et al. Ovulation induction and in vitro fertilization in ystemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum. 2000 Mar;43(3):550–6. DOI: http://dx.doi.org/10.1002/1529-0131(200003)43:3<550::AID-ANR10>3.0.CO;2-Y.
10. Buckingham KL, Stone PR, Smith JF, Chamley LW. Antiphospholipid antibodies in serum and follicular fluidis there a correlation with IVF implantation failure? Hum Reprod. 2006 Mar;21(3):728–34. Epub 2005 Oct 27. DOI: http://dx.doi.org/10.1093/humrep/dei369.
11. Hench PS. The ameliorating effect of pregnancy on chronic atrophic (infectious rheumatoid) arthritis, fibrositis and intermittent hydrarthritis. Mayo Clin Proc. 1935;13:161–7.
12. Ostensen M, Fuhrer L, Mathieu R, et al. A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann Rheum Dis. 2004 Oct;63(10):1212–7. DOI: http://dx.doi.org/10.1136/ard.2003.016881.
13. De Man YA, Bakker-Jonges LE, Goorbergh CM, et al. Women with rheumatoid arthritis negative for anti-cyclic citrullinated peptide and rheumatoid factor are more likely to improve during pregnancy, whereas in autoantibody-positive women autoantibody levels are not influenced by pregnancy. Ann Rheum Dis. 2010 Feb;69(2):420–3. DOI: 10.1136/ard.2008.104331.
14. Hazes JMW, Coulie PG, Geenen V, et al. Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use. Rheumatology (Oxford). 2011;50(11):1955–68. DOI: 10.1093/rheumatology/ker302. Epub 2011 Sep2.Review.
15. Brennan P, Silman A. Breast-feeding and the onset of rheumatoid arthritis. Arthritis Rheum. 1994 Jun;37(6):808–13. DOI: http://dx.doi.org/10.1002/art.1780370605.
16. Barrett JH, Brennan P, Fiddler M, Silman A. Breast-feeding and postpartum relapse in women with rheumatoid and inflammatory arthritis. Arthritis Rheum. 2000 May;43(5):1010–5. DOI: http://dx.doi.org/10.1002/1529-0131(200005)43:5<1010::AIDANR8>3.0.CO;2-O.
17. Gayed M, Gordon C. Pregnancy and rheumatic diseases. Rheumatology (Oxford). 2007 Nov;46(11):1634–40. DOI: http://dx.doi.org/10.1093/rheumatology/kem156. Epub 2007 Jul 10.
18. Iijima T, Tada H, Hidaka Y, et al. Prediction of postpartum onset of rheumatoid arthritis. Ann Rheum Dis. 1998 Aug;57(8):460–3. DOI: http://dx.doi.org/10.1136/ard.57.8.460.
19. Barrett JH, Brennan P, Fiddler M, Silman AJ. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Arthritis Rheum. 1999 Jun;42(6):1219–27. DOI: http://dx.doi.org/10.1002/1529-0131(199906)42:6<1219::AIDANR19>3.0.CO;2-G.
20. Perselin RH. The effect of pregnancy on rheumatoid arthritis. Bull Rheum Dis. 1976–1977;27(9):922–7.
21. Deighton CM, Sykes H, Walder DJ. Rheumatoid arthritis, HLA identity, and age at menarche. Ann Rheum Dis. 1993 May;52(5):322–6.
22. Silman AJ. Parity status and the development of rheumatoid arthritis. Am J Reprod Immumol. 1992;28(3–4):228–30. DOI: http://dx.doi.org/10.1111/j.1600-0897.1992.tb00799.x.
23. Silman AJ, Kay A, Brennan P. Timing of pregnancy in relation to the onset of rheumatoid arthritis. Arthritis Rheum. 1992 Feb;35(2):152–5. DOI: http://dx.doi.org/10.1002/art.1780350205.
24. Munoz-Valle JF, Vazquez-Del MM, Garcia-Iglesias T, et al. T(H)1/T(H)2 cytokine profile, metalloprotease-9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus patients. Clin Exp Immunol. 2003 Feb;131(2):377–84. DOI: http://dx.doi.org/10.1046/j.1365-2249.2003.02059.x.
25. Belcher C, Doherty M, Crouch SPM. Synovial fluid neutrophil function in RA: the effect of pregnancy associated proteins. Ann Rheum Dis. 2002 Apr;61(4):379–80. DOI: http://dx.doi.org/10.1136/ard.61.4.379.
26. Nelson JL, Hughes KA, Smith AG, et al. Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med. 1993 Aug 12;329(7):466–71. DOI: http://dx.doi.org/10.1056/NEJM199308123290704.
27. Nelson JL, Ostensen M. Pregnancy and rheumatoid arthritis. Rheum Dis Clin North Am. 1997 Feb;23(1):195–212. DOI: http://dx.doi.org/10.1016/S0889-857X(05)70323-9.
28. Lin HC, Chen SF, Chen YH. Increased risk of adverse pregnancy outcomes in women with rheumatoid arthritis: a nationwide population- based study. Ann Rheum Dis. 2010;69(4):715–7. DOI: http://dx.doi.org/10.1136/ard.2008.105262.
29. Norgaard M, Larsson H, Pedersen I, et al. Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence study. J Intern Med. 2010;268(4):329–37. DOI: 10.1111/j.1365- 2796.2010.02239.x.
30. Kaplan D, Diamond H. Rheumatoid arthritis and pregnancy. Clin Obstet Gynecol. 1965;8:286. DOI: http://dx.doi.org/10.1097/00003081-196506000-00004.
31. Reed SD, Vollan TA, Svec MA. Pregnancy outcomes in women with rheumatoid arthritis in Washington State. Matern Child Health J. 2006 Jul;10(4):361–6. DOI: http://dx.doi.org/10.1007/s10995-006-0073-3.
32. Ateka-Barrutia O, Nelson-Piercy C. Management of rheumatologic diseases in pregnancy. Int J Clin Rheumatol. 2012;7(5):541–58. DOI: http://dx.doi.org/10.2217/ijr.12.54.
33. Ostensen M, Lockshin M, Doria A, et al. Update on safety during pregnancy of biological agents and some immunosuppressive antirheumatic drugs. Rheumatology (Oxford). 2008 Jun;47 Suppl 3:iii28–31. DOI: 10.1093/rheumatology/ken168.
34. Bowden AP, Barrett JH, Fallow W, Silman AJ. Women with inflammatory polyarthritis have babies of lower birth weight. J Rheumatol. 2001 Feb;28(2):355–9.
35. Motta M, Tincani A, Meroni PL, Cimaz R. Follow-up children exposed antenatally to immunosuppressive drugs. Rheumatology (Oxford). 2008 Jun;47 Suppl 3:iii32–34. DOI: 10/rheumatology/ken149.
36. Matthews SG. Antenatal glucocorticoids and programming of the developing CNS. Pediatr Res. 2000 Mar;47(30):291–300.
37. Spinillo A, Viazzo F, Colleoni R, et al. Two-year infant neurodevelopmental outcome after single or multiple antenatal courses of corticosteroids to prevent complications of prematurity. Am J Obstet Gynecol. 2004 Jul;191(1):217–24. DOI: http://dx.doi.org/10.1016/j.ajog.2003.12.023.
38. Brucato A, Astori MG, Cimaz R, et al. Normal neuropsychologycal development of children with congenital complete heart block exposed or not in utero to high dose dexamethasone. Ann Rheum Dis. 2006 Nov;65(11):1422–6. DOI: http://dx.doi.org/10.1136/ard.2005.049866. Epub 2006 Feb 27.
39. Dalziel SR, Walker NK, Parag V, et al. Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of randomized controlled trial. Lancet. 2005;365(9474):1856–62.
40. DOI: http://dx.doi.org/10.1016/S0140-6736(05)66617-2.
41. Chikanza IC, Petrou P, Chrousos G, et al. Excessive and dysregulated secretion of prolactin in rheumatoid arthritis: immunopathogenetic and therapeutic implications. Br J Rheumatol. 1993 Jun;32(6):445–8. DOI: http://dx.doi.org/10.1093/rheumatology/32.6.445.
42. Brun JG, Nilssen S, Kvale G. Breast feeding, other reproductive factors and rheumatoid arthritis: A prospective study. Br J Rheumatol. 1995 Jun;34(6):542–6. DOI: http://dx.doi.org/10.1093/rheumatology/34.6.542.
43. Drossaers-Bakker KW, Zwinderman AH, van Zeben D, et al. Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis. Ann Rheum Dis. 2002 May;61(5):405–8. DOI: http://dx.doi.org/10.1136/ard.61.5.405.
44. Chambers CD, Tutuncu ZN, Johnson D, Jones KL. Human pregnancy safety for agents used to treat rheumatoid arthritis: adequace of available information and strategies for developing post-marketing data. Arthritis Res Ther. 2006;8(4):225–35. DOI: http://dx.doi.org/10.1186/ar1977.
45. Lockshin MD. Treating rheumatic diseases in pregnancy: dos and don'ts. Ann Rheum Dis. 2006 Nov;65 Suppl 3:iii58–60. DOI: http://dx.doi.org/10.1136/ard.2006.058420.
46. Ostensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8(3):209. DOI: http://dx.doi.org/10.1186/ar1957.Epub 2006 May 11.
47. Кошелева НМ. Терапия генно-инженерными биологическими препаратами и беременность. В кн.: Генноинженерные биологические препараты в лечении ревматоидного артрита. Под ред. Е.Л. Насонова. Москва: ИМА-ПРЕСС; 2013. С. 467–75. [Kosheleva NM. Therapy by genetically engineered biological preparations and pregnancy. In: Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological preparations in treatment of rheumatoid arthritis]. Nasonov EL, editor. Moscow: IMA-PRESS; 2013. P. 467–75.]
48. Gordon PA. Congenital heart block: clinical features and therapeutic approaches. Lupus. 2007;16:642–6. DOI: http://dx.doi.org/10.1177/0961203307079041.
49. Mitchell K, Clowse ME. The management of rheumatic diseases in pregnancy. Scand J Rhematol. 2010 Mar;39(2):99–108. DOI: 10.3109/03009740903449313.
50. Cote CJ, Meuwissen HJ, Pickering RJ. Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J Pediatr. 1974;85:324–8. DOI: http://dx.doi.org/10.1016/S0022-3476(74)80109-5.
51. Mendonca LL, Khamashta MA, Nelson-Piercy C, Hughes GRV. Non-steroidal anti-inflammatory drugs as a possible cause for reversible infertility. Rheumatology (Oxford). 2000;39:880–2. DOI: http://dx.doi.org/10.1093/rheumatology/39.8.880.
52. Uhler ML, Hsu JW, Fisher SG, Zunaman MJ. The effect of nonsteroidal anti-inflammatory drugs on ovulation: a prospective, randomized clinical trial. Fertil Steril. 2001;76:957–61. DOI: http://dx.doi.org/10.1016/S0015-0282(01)02829-1
53. Li DK, Liu L, Odouli R. Exposure of nonsteroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ. 2001;327:368–73. DOI: http://dx.doi.org/10.1136/bmj.327.7411.368.
54. Levy M, Buskula D, Gladmann DD, et al. Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol. 1991 May;8(3):174–8. DOI: http://dx.doi.org/10.1055/s-2007- 999371.
55. Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 2003 Nov;48(11):3207–11. DOI: http://dx.doi.org/10.1002/art.11304.
56. Rahimi R, Nikfar S, Resaie A, Abdollahi M. Pregnancy outcomes in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a metaanalysis. Reprod Toxicol. 2008;25:271–5. DOI: http://dx.doi.org/10.1016/j.reprotox. 2007.11.010.
57. Hoo JJ, Hadro TA, Von Behren P. Possible teratogenicity of sulfasalazine. N Engl J Med. 1988 Apr;318(17):1128. DOI: http://dx.doi.org/10.1056/NEJM198804283181713.
58. Craxi A, Pagliarello F. Possible embryotoxicity of sulfasalazine. Arch Intern Med. 1980 Dec;140(12):1674. DOI: http://dx.doi.org/10.1001/archinte.1980.00330230120030.
59. Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breastfeeding. Inflamm Bowel Dis. 2010 May;16(5):881–95. DOI: http://dx.doi.org/10.1002/ibd.21154.
60. Elliott AB, Chakravarty EF. Immunosuppressive medications during pregnancy and lactation in women with autoimmune diseases. Women's Health. 2010;6(3):431–42. DOI: http://dx.doi.org/10.2217/whe.10.24.
61. Roubenoff R, Hoyt J, Petry M, et al. Effects of anti-inflammatory and immunosuppressive drugs on pregnancy and fertility. Semin Arthritis Rheum. 1988 Nov;18(2):88–110. DOI: http://dx.doi.org/10.1016/0049-0172(88)90002-9.
62. Ostensen M. Current recommendations in the use of biologics for the treatment of rheumatic diseases in pregnant patients. Int J Clin Rheumatol 2011;6:597–600. DOI: http://dx.doi.org/10.2217/ijr.11.49.
63. Ostensen M., Motta M. Therapy insight: the use of antirheumatic drugs during nursing. Nat Clin Pract Rheumatol. 2007 Jul;3(7):400–6.
64. McKenzie SA, Selley JA, Agnew JE. Secretion of prednisolone into brest milk. Arch Dis Child. 1975;50(11):894–6. DOI: http://dx.doi.org/10.1136/adc.50.11.894.
65. Grekas DM, Vasiliou SS, Lazarides A.N. Immunosuppressive therapy and breast-feeding after renal transplantation. Nephron. 1984;37(1):68. DOI: http://dx.doi.org/10.1159/000183213.
66. Tett SE, Cutler DJ, Day RO, Brown KF. Biovailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol. 1989 Jun;27(6):771–9. DOI: http://dx.doi.org/10.1111/j.1365- 2125.1989.tb03439.x.
67. Ostensen M, Brown ND, Chang PK, Aarbakke J. Hydroxychloroquine in human breast milk. Eur J Clin Pharmacol. 1985;28(3):357. DOI: http://dx.doi.org/10.1007/BF00543338.
68. Costedoat-Chalumeau N, Amoura Z, Aymard G, et al. Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum. 2002 Apr;46(4):1123–4. DOI: http://dx.doi.org/10.1002/art.10150.
69. Cimaz R, Brucato A, Meregalli E, et al. Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: comment on the article by Costedoat-Chalumeau et al. Arthritis Rheum. 2004 Sep;50(9):3056–7. DOI: http://dx.doi.org/10.1002/art.20648.
70. Motta M, Tincani A, Faden D, et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol. 2005 Feb;25(2):86–9. DOI: http://dx.doi.org/10.1038/sj.jp.7211208.
71. Jä rnerot G, Into-Malmberg MB. Sulphasalazine treatment during breast feeding. Scand J Gastroenterol. 1979;14(7):869–71. DOI: http://dx.doi.org/10.3109/00365527909181418.
72. Ambrosius Christensen L, Rasmussen SN, Hansen SH, et al. Sulphasalazine and metabolites in fetal and maternal body fluids with special reference to 5-aminosalicylic acid. Acta Obstet Gynecol Scand. 1987;66(5):433–5. DOI: http://dx.doi.org/10.3109/00016348709022049.
73. Esbjö omer E, Jä rnerot G, Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand. 1987 Jan;76(1):137–42. DOI: http://dx.doi.org/10.1111/j.1651-2227.1987.tb10430.x.
74. Branski D, Ktrem E, Gross-Kieselstein E, et al. Bloody diarrhea –a possible complication of sulphasalazine transferred through human breast milk. J Pediatr Gastroenterol Nutr. 1986 Mar- Apr;5(2):316–7. DOI: http://dx.doi.org/10.1097/00005176-198605020-00028.
75. Nells GF. Diarrhoea due to 5-aminosalicylic acid in breast milk. Lancet. 1989;1:383. DOI: http://dx.doi.org/10.1016/S0140-6736(89)91754-6.
76. Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion of methotrexate into human milk. Am J Obstet Gynecol. 1972 Apr;112(7):978–80.
77. Coulam CB, Moyer TP, Jiang NS, Zinke H. Breast-feeding after renal transplantation. Transplant Proc. 1982 Sep;14(3):605–9.
78. Moretti ME, Verjee Z, Ito S, Koren G. Breast-feeding during maternal use of azathioprine. Ann Pharmacother. 2006 Dec;40(12):2269–72. Epub 2006 Nov 28. DOI: http://dx.doi.org/10.1345/aph.1H152.
79. Gardiner SJ, Gearry RB, Roberts RL, et al. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br J Clin Pharmacol. 2006 Oct;62(4):453–6. DOI: http://dx.doi.org/10.1111/j.1365-2125.2006.02639.x.
80. Nyberg G, Haljamä e U, Frisenette-Fich C, et al. Breast-feeding during treatment with cyclosporine. Transplatation. 1998 Jan;65(2):253–5. DOI: http://dx.doi.org/10.1097/00007890- 199801270-00019.
81. Moretti ME, Sgro M, Johnson DW, et al. Cyclosporine excretion into breast milk. Transplatation. 2003 Jun;75(12):2144–6. DOI: http://dx.doi.org/10.1097/01.TP.0000066352.86763.D0.
82. Munoz-Flores-Thiagarajan KD, Eastelig T, Davis C, Bond EF. Breast-feeding by a cyclosporine-treated mother. Obstet Gynecol. 2001 May;97(5 Pt 2):816–8. DOI: http://dx.doi.org/10.1016/S0029-7844(01)01122-X.
83. Thiru Y, Bateman DN, Coulthard MG. Successful breast feeding while mother was taking cyclosporine. BMJ. 1997 Aug;315(7106):463. DOI: http://dx.doi.org/10.1136/bmj.315.7106.463.
84. Ostensen M, Eigenmann GO. Etanercept in breast milk. J Rheumatol. 2004 May;31(5):1017–8.
85. Peltler M, James D. Infliximab levels in breast-milk of a nursing Crohn's patien [abstract]. Am J Gastroenterol. 2001;96:S312. DOI: http://dx.doi.org/10.1016/S0002-9270(01)03768-6.
86. Fö rger F. Infliximab in breast milk [abstract]. Lupus. 2004;13:753.
87. Vasiliauskas EA, Church JA, Silverman N, et al. Evidence for transplacental transfer of maternally administered infliximab to the newborn. Gastroenterol Hepatol. 2006 Oct;4(10):1255–8. DOI: http://dx.doi.org/10.1016/j.cgh.2006.07.018.
Рецензия
Для цитирования:
Кошелева Н.М., Матьянова Е.В. Ревматоидный артрит и беременность. Научно-практическая ревматология. 2014;52(6):589-599. https://doi.org/10.14412/1995-4484-2014-589-599
For citation:
Kosheleva N.M., Matyanova E.V. RHEUMATOID ARTHRITIS AND PREGNANCY. Rheumatology Science and Practice. 2014;52(6):589-599. (In Russ.) https://doi.org/10.14412/1995-4484-2014-589-599
Просмотров:
3640
Послать статью по эл. почте 